|View printer-friendly version|
Exicure Announces License and Development Agreement with Dermelix Biotherapeutics in Rare Genetic Skin Diseases
– Agreement Leverages Recent Clinical Success of
“Late last year we demonstrated the safety and clinical efficacy of our
platform in a Phase 1 clinical trial in patients with psoriasis.
Building on this success, we are now excited to extend the application
of our SNA technology into rare dermatological conditions,” said Dr.
Dermelix will initially develop a targeted therapy for the treatment of Netherton Syndrome (NS). NS is a rare and severe autosomal recessive disorder caused by loss-of-function mutations in the SPINK5 gene, which encodes the serine protease inhibitor LEKTI involved in skin barrier function. NS affects approximately 1 in 200,000 children born each year, and is characterized by severely inflamed, red, scaled, itchy skin, and patients are at increased risk of mortality in the first year of life due to recurrent infections and dehydration as a result of the impaired skin barrier. Currently, there are no approved treatments for NS patients and off-label use of standard of care treatments are of limited utility.
Under the terms of the agreement,
Dermelix is a privately-held, clinical-stage biopharmaceutical company focused on the development of innovative therapies for rare and debilitating dermatologic conditions with high unmet medical need. For more information, please visit http://www.dermelix.com/.
Forward Looking Statements
This press release contains forward-looking statements (including within
the meaning of Section 21E of the United States Securities Exchange Act
of 1934, as amended, and Section 27A of the United States Securities Act
of 1933, as amended) concerning the Company, the Company’s technology,
potential therapies and other matters. Forward-looking statements
generally include statements that are predictive in nature and depend
upon or refer to future events or conditions, and include words such as
“may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,”
“look forward,” and other similar expressions among others. Statements
that are not historical facts are forward-looking statements.
Forward-looking statements are based on current beliefs and assumptions
that are subject to risks and uncertainties and are not guarantees of
future performance. Actual results could differ materially from those
contained in any forward-looking statement as a result of various
factors, including, without limitation: unexpected costs, charges or
expenses that reduce cash runway; that Exicure’s pre-clinical programs,
including the announced partnership to treat rare genetic skin diseases
do not advance into the clinic or result in approved products on a
timely or cost effective basis or at all; the cost, timing and results
of clinical trials; possible safety and efficacy concerns; regulatory
developments; and the ability of
Exicure Media Contacts:
MacDougall Biomedical Communications
Exicure Investor Contacts:
The Del Mar Consulting Group, Inc.
Robert Prag, President